Showing results (31-40 of 45) with videos related to
Sort By:
Pageof 5
Current Medical Research and Opinion|August 2, 2022
Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancerSabin Goktas Aydin, Burcin Cakan Demirel, Ahmet Bilici, et al.Biomolecules & Biomedicine|June 8, 2023
Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center studySabin Goktas Aydin, Engin Eren Kavak, Atakan Topcu, et al.Cancer Medicine|December 23, 2023
The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (TOG) studyDeniz Can Guven, Musa Baris Aykan, Harun Muglu, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 15, 2025
Evaluating the prognostic role of glucose-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in first line: a study by the Turkish Oncology Group Kidney Cancer Consortium (TKCC)Hatice Bolek, Omer Faruk Kuzu, Elif Sertesen Camoz, et al.Current Medical Research and Opinion|May 29, 2024
Evaluation of the efficacy and safety of nivolumab in the second- or later-line treatment of patients with locally advanced/metastatic non-small cell lung cancer in Türkiye: a retrospective multicenter non-interventional registry studyNuri Karadurmus, Muhammet Ali Kaplan, Mehmet Ali Nahit Sendur, et al.Journal of Cancer Research and Therapeutics|December 17, 2021
Merkel cell carcinoma in Turkey: A multicentric studyFatih Yildiz, Umut Demirci, Ahmet Küçükarda, et al.Journal of Clinical Medicine|August 28, 2025
Comparison of Frontline FOLFIRINOX with Fluorouracil-Based and Gemcitabine-Based Chemotherapies in Metastatic Ampullary Adenocarcinoma: A Multicenter Study by the Turkish Oncology Group (TOG)Ali Kalem, Tulay Kus, Savas Gokcek, et al.Cancers|September 13, 2025
FOLFIRINOX: The Best Adjuvant Treatment for Ampullary Adenocarcinoma? A Multicenter Study by the Turkish Oncology Group (TOG)Ali Kalem, Tulay Kus, Taha Koray Sahin, et al.Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|June 12, 2020
Does primary tumor localization has prognostic importance in seminoma patients?: Turkish Oncology Group StudyBirol Yildiz, Ahmet Kucukarda, Ali Gokyer, et al.Cancer Immunology, Immunotherapy : CII|March 24, 2026
Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV)Veronica Mollica, Francesco Massari, Kazutoshi Fujita, et al.Pageof 5